Skip to main navigation Skip to search Skip to main content

Melanoma

  • Daniel G. Coit
  • , Robert Andtbacka
  • , Christopher J. Anker
  • , Christopher K. Bichakjian
  • , William E. Carson
  • , Adil Daud
  • , Raza A. Dilawari
  • , Dominick DiMaio
  • , Valerie Guild
  • , Allan C. Halpern
  • , F. Stephen Hodi
  • , Mark C. Kelley
  • , Nikhil I. Khushalani
  • , Ragini R. Kudchadkar
  • , Julie R. Lange
  • , Anne Lind
  • , Mary C. Martini
  • , Anthony J. Olszanski
  • , Scott K. Pruitt
  • , Merrick I. Ross
  • Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist
  • Memorial Sloan-Kettering Cancer Center
  • University of Utah
  • University of Michigan, Ann Arbor
  • Ohio State University
  • University of California at San Francisco
  • University of Tennessee System
  • Nebraska Medicine
  • AIM at Melanoma Foundation
  • Dana-Farber/Brigham and Women's Cancer Center
  • Vanderbilt University
  • Roswell Park Cancer Institute
  • University of South Florida
  • Johns Hopkins University
  • Washington University St. Louis
  • Northwestern University
  • Duke University
  • University of Texas MD Anderson Cancer Center
  • Stanford University
  • Massachusetts General Hospital Cancer Center
  • Seattle Cancer Care Alliance
  • City of Hope National Medical Center
  • University of Alabama at Birmingham

Research output: Contribution to journal › Review article › peer-review

70 Scopus citations

Abstract

These guidelines represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms. In general, treatment recommendations for primary tumors are based on better data than those for treating recurrent disease. Few, if any, firm recommendations can be made about more controversial issues for patients with melanoma, such as the extent of workup or intensity of follow-up. These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by clinician judgment and other factors, such as local resources and expertise and the individual patient's needs, wishes, and expectations. Furthermore, these guidelines undergo annual revision and are continually updated as new data become available.

Original languageEnglish
Pages (from-to)366-400
Number of pages35
JournalJournal of the National Comprehensive Cancer Network
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adjuvant therapy
  • Biopsy
  • Chemotherapy
  • Interferon
  • Lymph node dissection
  • Margin
  • Melanoma
  • Metastases
  • NCCN clinical practice guidelines
  • NCCN guidelines
  • Pathology
  • Radiation therapy
  • Sentinel lymph node
  • Skin cancer
  • Surgical excision

Fingerprint

Dive into the research topics of 'Melanoma'. Together they form a unique fingerprint.

Cite this